# First Evaluation of Drug-Resistant Mycobacterium tuberculosis Clinical Isolates from Congo Revealed Mis detection of Fluoroquinolone Resistance by Line Probe Assay Due to a Double Substitution T80A-A90G in GyrA

Alexandra Aubry, Wladimir Sougakoff, Pamela Bodzongo, Guy Delcroix, Sylvie Armand, Gérald Millot, Vincent Jarlier, René Courcol, Nadine Lemaitre

<figure><img src="image_1.png" /></figure>

To cite this version:

Alexandra Aubry, Wladimir Sougakoff, Pamela Bodzongo, Guy Delcroix, Sylvie Armand, et al. First Evaluation of Drug-Resistant Mycobacterium tuberculosis Clinical Isolates from Congo Revealed Mis-detection of Fluoroquinolone Resistance by Line Probe Assay Due to a Double Substitution T80A-A90G in GyrA. PLoS ONE, 2014, 9 (4), pp.e95083. 10.1371/journal.pone.0095083. hal-01344539

HAL Id: hal-01344539

https://hal.sorbonne-universite.fr/hal-01344539v1

Submitted on 12 Jul 2016

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
# First Evaluation of Drug-Resistant *Mycobacterium tuberculosis* Clinical Isolates from Congo Revealed Misdetection of Fluoroquinolone Resistance by Line Probe Assay Due to a Double Substitution T80A-A90G in GyrA

Alexandra Aubry<sup>1,2,3</sup>, Wladimir Sougakoff<sup>1,2,3</sup>, Pamela Bodzongo<sup>4</sup>, Guy Delcroix<sup>5</sup>, Sylvie Armand<sup>5</sup>, Gérald Millot<sup>3</sup>, Vincent Jarlier<sup>1,2,3</sup>, René Courcol<sup>5,6,7,8</sup>, Nadine Lemaître<sup>5,6,7,8*</sup>

1 UPMC Université, Paris, France, 2 INSERM U1135, Paris, France, 3 Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France, 4 Faculté des Sciences de la Santé, Brazzaville, Congo, 5 Laboratoire de Bactériologie-Hygiène du CHRU, Lille, France, 6 Université Lille Nord de France, Lille, France, 7 UDSL, F-59000 Lille, France, 8 INSERM U1019-UMR8204, Lille, France

## Abstract

**Background:** Tuberculosis (TB) is one of the major public health problems in Congo. However, data concerning *Mycobacterium tuberculosis* drug resistance are lacking because of the insufficient processing capacity. So, the aim of this study was to investigate for the first time the resistance patterns and the strain lineages of a sample of *M. tuberculosis* complex (MTBC) isolates collected in the two main cities of Congo.

**Methods:** Over a 9-day period, 114 smear-positive sputa isolated from 114 patients attending centers for the diagnosis and treatment of TB in Brazzaville and Pointe Noire were collected for culture and drug susceptibility testing (DST). Detection of mutations conferring drug resistance was performed by using line probe assays (GenoType MTBDRplus and MTBDRsl) and DNA sequencing. Strain lineages were determined by MIRU-VNTR genotyping.

**Results:** Of the 114 sputa, 46 were culture positive for MTBC. Twenty-one (46%) were resistant to one or more first-line antiTB drugs. Of these, 15 (71%) were multidrug resistant (MDR). The most prevalent mutations involved in rifampin and isoniazid resistance, D516V (60%) in *rpoB* and S315T (87%) in *katG* respectively, were well detected by MTBDRplus assay. All the 15 MDR strains were susceptible to fluoroquinolone and injectable second-line drug. No mutation was detected in the *rrs* locus involved in resistance to amikacin and capreomycin by both the MTBDRsl assay and DNA sequencing. By contrast, 9 MDR strains belonging to the same cluster related to T-family were identified as being falsely resistant to fluoroquinolone by the MTBDRsl assay due to the presence of a double substitution T80A-A90G in GyrA.

**Conclusions:** Taken together, these data revealed a possible spread of a particular MDR clone in Congo, misidentified as fluoroquinolone resistant by MTBDRsl assay. Thus, this test cannot replace gold-standard culture method and should be interpreted carefully in view of the patient's native land.

**Citation:** Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, et al. (2014) First Evaluation of Drug-Resistant *Mycobacterium tuberculosis* Clinical Isolates from Congo Revealed Misdetection of Fluoroquinolone Resistance by Line Probe Assay Due to a Double Substitution T80A-A90G in GyrA. PLoS ONE 9(4): e95083.
doi:10.1371/journal.pone.0095083

**Editor:** Igor Mokrousov, St. Petersburg Pasteur Institute, Russian Federation

**Received:** February 14, 2014; **Accepted:** March 21, 2014; **Published:** April 17, 2014

**Copyright:** © 2014 Aubry et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the Centre National de Lutte contre le SIDA from Congo. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Tuberculosis (TB) remains an important cause of morbidity and mortality in 2012 with 8.6 million cases and 1.3 million deaths worldwide [1]. Sub Saharan Africa is particularly affected with approximately 1.3 million new cases. Congo is a West Africa country with a population of ~4 million people. As in many sub Saharan Africa countries, TB is a major health problem in Congo despite the implementation of the Directly Observed Therapy Short course (DOTS) strategy in the mid-1990. The World Health

Organization estimated the incidence of all forms of TB in Congo at 381/100,000 and mortality at 42/100,000 in 2012 [1]. Among the new TB cases, the rate of HIV patients reaches 33%. Thus, Congo is considered a "high burden" country for TB and HIV infection. The Global Plan to STOP TB (2006–2015) recommends knowing early the drug susceptibility status, especially in case of retreatment. During the past few years, several molecular techniques including reverse hybridization assay with DNA probes have been developed to quickly predict drug resistance in clinical

<footnote>* E-mail: nadine.lemaitre@chru-lille.fr</footnote>
isolates of *Mycobacterium tuberculosis* complex (MTBC) and thereby
to facilitate appropriate patient management. GenoType
MTBDRplus demonstrated a good concordance with phenotypic
drug susceptibility testing and has been approved by the WHO for
rapid screening of patients at risk of MDR-TB. Unfortunately,
routine drug susceptibility testing (DST) is not implemented in
Congo due to the lack of laboratory capacity for mycobacterial
culture, and molecular methods targeting drug resistance muta-
tions. As in other African countries, smear microscopy is the
primary method used for diagnosing TB in Congo, and if
diagnosed, a standardized supervised treatment is set, with the
following regimens: 2HRZE/4HR and 2HRZES/1HRZE/
5HRE (H: isoniazid, R: rifampin, Z: pyrazinamide, E: ethambutol
and S: streptomycin) for new and previously treated TB cases,
respectively. Consequently, to date, no study has been conducted
in this country to reflect the situation in term of resistance
phenotypes and molecular mechanisms of resistance. This study
represents the first phenotypic and molecular study of tuberculosis
in Congo with the goal to (i) determine drug susceptibility patterns
in samples collected in the two main Congo's cities (Brazzaville
and Pointe-Noire) that account for two third of the population and
(ii) characterize mutations prevalent in clinical isolates by using the
commercially available GenoType MTBDRplus and GenoType
MTBDRsl assays, as well as DNA sequencing [2,3]. Furthermore,
to gain an insight into the epidemiology of these MTBC isolates, a
molecular typing by determination of the MIRU-VNTR patterns
was also performed. Based on the results obtained, we report for
the first time the presence of MDR but not XDR strains in Congo.
We also showed that reverse hybridization assay with DNA probes
falsely detected fluoroquinolones resistance in a predominant
MDR clone harboring a double substitution T80A-A90G known
to confer hypersusceptibility to fluoroquinolones [4,5,6]. This
emphasized that detection of gyrA mutations by line probe assay
should be interpreted with caution and cannot replace conven-
tional drug susceptibility testing in countries such as Congo.

**Materials and Methods**

Ethics statement

Ethical approval for this study was obtained from the Faculty of Sciences de la Santé of Congo review committee. Informed written consent was waived by the IRB because all data and sampling were collected during the course of routine care in patients registered at the DOTS centers for suspicion of pulmonary TB or TB treatment. This study did not require any additional data, sampling and contact with patients. The outcome of the research data did not affect patient management. The objectives of the study were verbally explained to all participants. They were free to refuse that their sputum was transported to TB reference laboratories in France for processing and culture. No personal identifiers were recorded to maintain anonymity and confidentiality.

Patients and specimens

One smear-positive sputum per patient was collected over a 9-
day period from 114 patients attending 6 centers for the diagnosis
and treatment of TB of the two largest cities of Congo (5 located in
Brazzaville and one located in Pointe Noire). Samples were studied
anonymously in combination with the available clinical informa-
tion including sex age, HIV status and past history of treatment.
All patients included in this study were previously untreated or
treated for less than a month at the time of collection of smear-
positive sputum.

Culture and antibiotic susceptibility testing

The 114 refrigerated sputa were shipped to the laboratory of bacteriology from the teaching hospital at Lille (France) for culture and determination of first-line drug susceptibility of isolates as well as mutations profiles associated with the resistance to antiTB drugs. Samples were processed by standard methods (N-acetyl L-cysteine-NaOH), followed by staining with auramine-rhodamine fluorochrome for microscopy and by culturing in a bactec MGIT 960 (Becton-Dickinson) non radiometric automatic isolation system [7–8]. Primary culture was characterized as belonging to MTBC using an immunochromatographic assay, based on detection of a specific MPT64 antigen (BIOCENTRIC, France). When the immunochromatographic assay was negative, identification of mycobacteria was done by 16S-23S rDNA internal transcribed spacers or Hsp65 sequencing [9,10]. A total of 46 samples were culture positive for MTBC and were used for determining the drug susceptibility profiles against the first-line drugs: isoniazid (0.1 µg/ml), rifampin (1.0 µg/ml), ethambutol (5 µg/ml) and streptomycin (1 µg/ml) by using the MGIT 960 system according to the manufacturer's instructions [11]. Isolates resistant to at least to isoniazid and rifampin were considered as multidrug resistant (MDR) isolates and underwent drug susceptibility testing with ofloxacin, moxifloxacin and amikacin to identify extensively drug resistant (XDR) TB isolates. The breakpoint concentrations of ofloxacin, moxifloxacin and amikacin with MGIT 960 system were 2, 0.5 and 1 µg/ml, respectively [12,13]. Two concentrations of ofloxacin and moxifloxacin were tested (1 and 2 µg/ml, and 0.25 and 0.5 µg/ml, respectively).

DNA extraction

For DNA preparation, 1 ml of bacteria cultured in MGIT was
used. Liquid cultures were centrifugated at 10,000 g for 15 min.
and the mycobacterial pellets were resuspended in 300 µl distilled
water and heat-killed at 95°C for 30 min. DNA used for
amplification by PCR was obtained by heat shock extraction (3
cycles of freezing at -80°C and boiling for 1 min.)

Detection of mutations in drug target genes in MTBC
isolates

In order to screen for resistance to rifampin and isoniazid, the GenoType MTBDRplus assay was performed as recommended by the manufacturer (Hain LifeScience, GmbH, Germany). In addition, MTBC isolates found to be MDR were tested by GenoType MTBDRsl assay, a line probe assay (LPA) that detects mutations associated with fluoroquinolone and injectable second-line drugs resistance. DNA sequencing in specific hot-spot target regions of the following genes: *rpoB* (rifampin resistance), *katG*, *inhA* and *inhA* promoter region (isoniazid resistance), *gyrA*, *gyrB* (fluoroquinolone resistance), *rpsL* and *rrs* (aminoglycoside resistance) was performed to characterize more precisely the pattern of mutation or to resolve discrepancies between LPA and DST. The primers used for the DNA sequencing are listed in Table 1. The PCR products were purified using a Machereł-Nagel PCR purification kit according to the manufacturer's instructions. The purified DNA was used for DNA sequencing with a 3500 Dx Genetic analyzer (Applied Biosystem) automated sequencer.

MIRU-VNTR typing

The MTBC culture positive isolates were further genotyped by
PCR amplification of a panel of 24 MIRU-VNTR loci at the
National Reference Centre for Mycobacteria (Pitié-Salpêtrière
hospital, Paris, France), as previously described by Supply *et al.*
[14]. Briefly, 2 µl of DNA extracted from cultures of the MTBC
<table><caption>**Table 1.** Designed primers used in this study for amplification of drug target genes.</caption><thead><tr><th>Locus</th><th>Primers</th><th>Sequence (5' to 3')</th><th>Position</th><th>Size (pb)</th></tr></thead><tbody><tr><td rowspan="2">promoter inhA</td><td>pro-F inhA</td><td>TCAATACACCCGCAGCCA</td><td>-189</td><td>491 pb</td></tr><tr><td>pro-R inhA</td><td>GTCATCCGCATGAGGAAT</td><td>302</td><td></td></tr><tr><td rowspan="2">inhA</td><td>inhA-F</td><td>GCATGGGTATGGGCCACT</td><td>-38</td><td>528 pb</td></tr><tr><td>inhA-R</td><td>GACCGTCATCCAGTTGTA</td><td>490</td><td></td></tr><tr><td rowspan="8">katG</td><td>katG1-F</td><td>GCCCGAGCAACACCCACC</td><td>3</td><td>705 pb</td></tr><tr><td>katG2-R</td><td>TTCGGCCCCTCCGGGTTC</td><td>708</td><td></td></tr><tr><td>katG3-F</td><td>CAGTGGGAGCCCGATGAG</td><td>568</td><td>721 pb</td></tr><tr><td>katG4-R</td><td>GCGGCCCAAGGTATCTCG</td><td>1289</td><td></td></tr><tr><td>katG5-F</td><td>CGCTCCCGACGATGCTG</td><td>1117</td><td>783 pb</td></tr><tr><td>katG6-R</td><td>GACGCGCAGGCCACCTAC</td><td>1900</td><td></td></tr><tr><td>katG7-F</td><td>CGTGCTGGAGCCCAAGGC</td><td>1755</td><td>446 pb</td></tr><tr><td>katG8-R</td><td>GGTTCATCACCTTGTCCC</td><td>2201</td><td></td></tr><tr><td rowspan="2">rpoB</td><td>rif-F</td><td>GCGTACGGTCGGCGAGCT</td><td>1361</td><td>419 pb</td></tr><tr><td>rif-R</td><td>CCTTGCGGTACGGCGTTT</td><td>1780</td><td></td></tr><tr><td rowspan="2">gyrA</td><td>gyrA-F</td><td>CGATTCCGGCTTCCGCCC</td><td>180</td><td>195 pb</td></tr><tr><td>gyrA-R</td><td>CGCCGGTGGGTCATTGCC</td><td>375</td><td></td></tr><tr><td rowspan="2">gyrB</td><td>gyrB-F</td><td>GAGTTGGTGCGGCGTAAG</td><td>1390</td><td>321 pb</td></tr><tr><td>gyrB-R</td><td>CGGCCATCAGCACGATCT</td><td>1711</td><td></td></tr><tr><td rowspan="2">rpsL</td><td>rspl-F</td><td>CCAACCATCCAGCAGCTG</td><td>4</td><td>305 pb</td></tr><tr><td>rspl-R</td><td>ATCCAGCGAACCGCGGAT</td><td>309</td><td></td></tr><tr><td rowspan="2">rrs</td><td>rrs3-F</td><td>TGGGTTAAGTCCCGAAC</td><td>1077</td><td>459 pb</td></tr><tr><td>rrs3-R</td><td>AAAGGAGGTGATCCAGCC</td><td>1536</td><td></td></tr></tbody></table>

doi:10.1371/journal.pone.0095083.t001

isolates was amplified using the 24 loci MIRU-VNTR typing kit (Genoscreen, Lille, France). Automated MIRU-VNTR analysis was performed on an ABI 3730 automatic sequencer (Applied Biosystems, California, USA). Estimation of the sizes of the amplified fragments was done using the Genemapper software (Applied Biosystems) with automated assignment of the alleles. Identification of the families and lineages was carried out by using the MIRU-VNTR plus online database.

## Statistical analysis

Epidemiological and laboratory analysis were done with EpiInfo (version 6.04). Associations between variables were explored using the X² test (or Fisher's exact test when expected cell sizes were less than five). A *p* value less than 0.05 was considered statistically significant.

## Results and Discussion

Of the 114 recruited cases, 81 and 33 were registered in the DOTS centers of Brazzaville and Pointe Noire, respectively. From the 114 sputa, a total of 46 and 5 cultures were positive for MTBC and *M. avium*, respectively. The rate of culture positive for MTBC was significantly higher (*p* = 0.002) in Pointe Noire (21/33, 64%) than in Brazzaville (25/81, 31%) while the rate of patients treated at the time of collection of smear-positive sputa (66% vs 60%, *p* = 0.53) as well as the delay between collection of specimens and the time of initiation of supervised treatment (means = 8.4±8.8 vs 11.0±11.8 days, *p* = 0.25) did not differ significantly among patients originating from these two cities. Thus, the treatment with the first-line drugs of TB cases from Pointe-Noire area appeared

less effective than in Brazzaville. Finally, 47 (41%) were culture negative and 16 (41%) were contaminated by oral flora.

A high frequency of resistance (21/46, 46%) to one or more first-line antiTB drugs was noted in the MTBC isolates tested for susceptibility with the MGIT 960 system (Table 2). Among the 21 resistant strains, 15 (71%) were MDR, 4 were isoniazid monoresistant, one was streptomycin monoresistant and one was resistant to both isoniazid and streptomycin. As expected, MDR was more significantly prevalent in the 9 patients with previous history of TB (78% vs 22%, *p* = 0.003) since all the 7 resistant strains isolated from the retreatment cases were MDR (Table 2). Alarmingly, the remaining 8 MDR-TB cases (53%) were found in the new cases suggesting a recent transmission of MDR-TB. The rate of MDRTB was comparable to the one observed in the hot-spot countries located in Eastern Europe and also in some countries of Africa such as Sierra Leone and Cameroon [1,15,16] and, largely exceeded the latest WHO's global estimation (3.1%). It is worth noting that the neighboring countries such as RD of Congo and Cameroon reported an increase in MDR-TB in recent years thus suggesting a possible spread of MDR-TB strains in this region of Africa [1,16]. The MDR-TB cases were not associated with HIV infection in the present study. By contrast, the proportion of MDR was significantly higher in culture-positive patients attending the DOTS center of Pointe-Noire compared to patients from the Brazzaville district (52% vs 16%, *p* = 0.02) thus, indicating a possible outbreak in the Pointe Noire area.

Rifampin resistance was only observed in MDR isolates. The hybridization patterns obtained with the MTBDRplus assay confirmed the resistance to rifampin detected by DST in all isolates, either by a positive hybridization signal with the MUT1 (RpoB substitution D516V) or MUT3 (RpoB substitution S531L), or the lack of hybridization with the wild-type probes WT2, WT3, WT4 and WT8. Nine of 15 MDR strains harbored the RpoB substitution D516V, whereas the RpoB substitution S531L commonly detected in MDR strains worldwide isolated, was found in two strains only [17,18]. All these substitutions were confirmed by rpoB DNA sequencing, which revealed an additional V577M substitution in a strain also harbouring the S531L substitution. Four remaining MDR strains, detected by the lack of hybridization with the wild-type probes WT2, WT3 and WT4 harbored rarely encountered rpoB mutations as shown by DNA sequencing: D516Y, S531Q, and double mutations L511R+D516Y and L511P+D516Y. In a previous study, single substitution at position 511 (L511P) and 516 (D516Y) were associated with discordant drug susceptibility results [19] while in the present study the combination of these substitutions were detected in highly rifampin-resistant strains.

Considering the 20 isoniazid-resistant strains, the hybridization patterns obtained with the MTBDRplus assay confirmed the resistance to isoniazid detected by DST in all, except 3 isolates. The most prevalent S315T substitution was found in 15 (75%) isolates both with the genotype MTBDRplus assay and DNA sequencing [17,18]. Mutations at the *inhA* position -15 (C→T) in the promoter site, corresponding to *inhA* MUT1 band, were only detected in two non MDR isolates which were characterized by a low level of resistance to INH. The three isoniazid-resistant strains not detected with MTBDRplus assay included two MDR strains exhibiting a H270P mutation and a large deletion of *katG* in the 5' part of the gene, respectively and one monoresistant to INH having a single *katG* missense mutation at codon 709 (E → K). Resistance to streptomycin which was not detectable by LPA assays was due to the presence of substitution K43R in *rpsL* of three MDR and one non MDR strains. Then, the 15 MDR isolates were screened for the identification of a XDR profile by
<table><caption>**Table 2.** MTBC clinical isolates susceptibilities to antimicrobial drugs.</caption><thead><tr><th></th><th>Sensitivity to all first-line drugs</th><th>Resistant to at least one drug but not to INH and RIF</th><th>MDR</th></tr></thead><tbody><tr><td>New cases of TB</td><td>23</td><td>6</td><td>8</td></tr><tr><td>Recurrent or relapse cases of TB</td><td>2</td><td>0</td><td>7*</td></tr></tbody></table>

*p* = 0.003 (patients with previous history of TB vs no previous history of TB). doi:10.1371/journal.pone.0095083.t002

DST to fluoroquinolones (ofloxacin and moxifloxacin) and injectable second-line drug (amikacin), and by genotypic MTBDRs1 assay. All the 15 MDR strains were susceptible to amikacin and fluoroquinolones thus excluding the presence of XDR strains in the Congo's isolates studied. The 15 MDR strains phenotypically susceptible to amikacin also harbored a wild-type nt 1400 region of rrs. In contrast, 9 of the 15 MDR strains, predicted by MGIT 960 to be susceptible to ofloxacin and moxifloxacin, were detected as potentially resistant to fluoroquinolones by MDRTBs1 assay by lack of hybridization with the WT2 probe while no hybridization was observed with all the mutation probes (MUT1, MUT2, MUT3 A→D) thus, indicating an unusual mutation in gyrA. A possible resistance to fluoroquinolone suggested by the MDRTBs1 results but remaining undetectable at the phenotypic level was unexpected since the second-line drug-based regimen has not yet been introduced in Congo. DNA sequencing of gyrA revealed that these 9 MDR strains harbored the same combination of GyrA T80A and A90G substitutions known to confer hypersusceptibility to fluoroquinolones [4–6]. We also sequenced gyrB because mutations in this gene that have been previously associated with fluoroquinolone resistance are not explored by the MTBDRs1 assay [20]. One MDR strain displayed the substitution G559A in GyrB but this mutation is not involved in fluoroquinolone resistance [21]. In our study, a GyrA T80A and A90G substitutions were also found in one strain susceptible to first-line drugs and the GyrB G559A substitution in three non MDR strains: two drug susceptible and one isoniazid monoresistant strains (data not shown). GyrA T80A and A90G and GyrB G559A substitutions may represent natural variations of M. tuberculosis resulting in false-resistance to fluoroquinolones by LPA which can lead to a XDR-TB misdiagnosis and unnecessary restriction of active drugs. Natural variations in the genome especially in the gyrA gene at position 73, (T73A) and 95 (S95T) have been previously reported in MTBC isolates from other African countries [22,23] and emphasized that LPA assay should be used and interpreted with caution in patients originating from these countries. Finally, second-line DST may be more accurate for the detection of second drugs in these resource-limited TB settings. For this purpose, recent studies highlighted the usefulness of the sensititre MycoTB plate method in low-income countries such as Tanzania and Uganda [24,25]. This method is rapid (the turnaround time is 10–15 days when the test is valid on the first try), ready to use (lyophilized first and second-line drugs with several dilutions), and requires minimal instrumentation (mirror box) [26]. This method could be useful for DST surveillance in Congo especially among patients receiving empirical MDR regimen that could be introduced in this country because of the absence or low-prevalence of fluoroquinolone and injectable aminoglycoside resistance.

Analysis of the dendrogram drawn from the MIRU-VNTR codes confirmed that the 9 MDR strains exhibiting the double mutation GyrA T80A and A90G, as well as the same mutations in rpoB and katG, were gathered into a unique cluster related to the T-

family. All except one of the 9 strains displayed an identical MIRU-VNTR. The last strain differed at the level of one locus among the 24 loci analyzed (Table 3) thus, suggesting a possible focal outbreak in Pointe Noire district since 6 strains of this clone were isolated from patients attending the DOTS center of Pointe-Noire. The one susceptible strain harboring the double mutation in gyrA was also related to the T-family too but was not included in the same cluster encompassing the nine T80A-A90G MDR strains. One MDR strain and the three non MDR strains displaying the GyrB G559A substitution were linked in the MIRU-VNTR dendrogram and were related to the T lineage suggesting that this substitution could be a marker of a subgroup of strains in the T family. Only 4 MTBC (3 MDR and one susceptible) isolates belonged to the Beijing family in our study. A similar low prevalence of Beijing family among MTBC isolates was previously reported in the West Africa countries [15,27,28], contrarily to Asia, Russia and the United States where the Beijing family predominates [29–32]. The 3 MDR Beijing strains that were closely related at the level of their MIRU-VNTR profile (Table 3) shared a D516Y substitution in RpoB and two of these had additional rpoB mutations at position 511. The two remaining MDR strains characterized by a S531 substitution in RpoB, were found to be related to the LAM family but had unique MIRU-VNTR codes, indicating that they were not related to any of the other MDR isolates (Table 3). Finally, MIRU-VNTR analysis revealed that a majority of the MTBC isolates included in our study (30 of 46, 65%) were related to the ill-defined T family which represents a group of strains showing a high degree of genetic diversity frequently encountered in Africa. The other genotypes found in the 46 strains analyzed were LAM (17%), Cameroon (9%) and Beijing (9%). The distribution of MIRU-VNTR families was similar between strains isolated in Pointe Noire and Brazzaville areas and between MDR and non MDR strains. No significant statistical link was found between lineages and epidemiological data such as age, sex and HIV status.

## Conclusions

By conducting the first phenotypic and molecular investigation of M. tuberculosis clinical isolates in circulation in Congo we have revealed the presence of MDR-TB in this country as well as the probable spread of a particular clone of double mutant GyrA T80A and A90G hypersusceptible to fluoroquinolones among MDR strains in this region of Africa. The presence of MDR-TB emphasizes the urgent need to perform molecular assays to rapidly detect drug resistance in order to start an appropriate antiTB treatment with second-line drugs in Congo. However, line probe assay may have limitation in detecting fluoroquinolone resistance in Congo since strains harboring specific mutations such as T80A-A90V in GyrA lead to false diagnosis of fluoroquinolone resistance. Therefore, a lack of hybridization with the wild type WT2 probe should not be interpreted as fluoroquinolone resistance until DNA sequencing and/or DST were performed.
<table><caption>Table 3. Characteristics of mutations in drug target genes from the 15 MDR-TB isolates.</caption><thead><tr><th rowspan="2">No. of isolates</th><th colspan="5">Drug target genes</th><th rowspan="2">MIRU-VNTR patterns</th><th rowspan="2">Spoligotyping based defined clades</th></tr><tr><th>rpoB</th><th>katG</th><th>rpsL</th><th>gyrA</th><th>gyrB</th></tr></thead><tbody><tr><td>N=8</td><td>D516V</td><td>S315T</td><td>wt</td><td>T80A+A90G</td><td>wt</td><td>253333253232237253214423</td><td>T</td></tr><tr><td>N=1</td><td>D516V</td><td>S315T</td><td>wt</td><td>T80A+A90G</td><td>wt</td><td>254333253232237253214423</td><td>T</td></tr><tr><td>N=1</td><td>S531L+V577M</td><td>H270P</td><td>wt</td><td>wt</td><td>G559A</td><td>255333143262325262213423</td><td>T</td></tr><tr><td>N=1</td><td>D516Y</td><td>S315T</td><td>K43R</td><td>wt</td><td>wt</td><td>273335444432455253213423</td><td>Beijing</td></tr><tr><td>N=1</td><td>L511R+D516Y</td><td>S315T</td><td>K43R</td><td>wt</td><td>wt</td><td>273335444432655253213423</td><td>Beijing</td></tr><tr><td>N=1</td><td>L511P+D516Y</td><td>S315T</td><td>K43R</td><td>wt</td><td>wt</td><td>273335444432655253213423</td><td>Beijing</td></tr><tr><td>N=1</td><td>S531L</td><td>S315T</td><td>K43R</td><td>wt</td><td>wt</td><td>251313542122437262112415</td><td>LAM</td></tr><tr><td>N=1</td><td>S531Q</td><td>Del</td><td>wt</td><td>wt</td><td>wt</td><td>251323142122234262213523</td><td>LAM</td></tr></tbody></table>

doi:10.1371/journal.pone.0095083.t003

## Acknowledgments

The authors thank the entire staff of the centers for the diagnosis and treatment of TB of Brazzaville and Pointe-Noire for their help in this study.

## References

1. WHO (2013) Global tuberculosis report. World Health Organization, Geneva, Switzerland.

2. Hillemann D, Rüsch-Gerdes S, Richter E (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45:2635–2640.

3. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W (2010) Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant *Mycobacterium tuberculosis* complex isolates. J Clin Microbiol 48:1683–1889.

4. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, et al. (2006) Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of *Mycobacterium tuberculosis*: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104–112.

5. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE (2012) New insights into fluoroquinolone resistance in *Mycobacterium tuberculosis*: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754.

6. Von Groll A, Martin A, Jureen P, Hofner S, Vandamme P, et al. (2009) Fluoroquinolone resistance in *Mycobacterium tuberculosis* and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53:4498–4500.

7. Kubica GP, Dye WE, Cohn ML, Middlebrook G (1963) Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of *mycobacteria*. Am Rev Dis 87:775–779.

8. Silver H, Sonnenwirth AC, Alex N (1966) Modifications in the fluorescence microscopy technique as applied to identification of acid-fast-bacilli in tissue and bacteriological material. J Clin Path 19:583–588.

9. Brunello F, Ligozzi M, Cristelli E, Bonora S, Tortoli E, et al. (2001) Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the *lsp65* gene. J Clin Microbiol 39:2799–2806.

10. Roth A, Reischl U, Streubel A, Naumann L, Kroppenstedt RM, et al. (2000) Novel diagnostic algorithm for identification of *mycobacteria* using genus-specific amplification of the 16S-23S rRNA gene spacer and restriction endonucleases. J Clin Microbiol 38:1094–1104.

11. Rüsch-Gerdes S, Domehl C, Nardi G, Gismondo MR, Welscher H-M, et al. (1999). Multicenter evaluation of the *Mycobacteria* Growth Indicator Tube for testing susceptibility of *Mycobacterium tuberculosis* to first-line drugs. J Clin Microbiol 37:45–48.

12. Rüsch-Gerdes S, Pfiffer GE, Casal M, Chadwick M, Siddiqi S (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of *Mycobacterium tuberculosis* to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44:688–692.

13. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, et al. (2010) Comparative study on genotypic and phenotypic second-line drug resistance testing of *Mycobacterium tuberculosis* complex isolates. J Clin Microbiol 48:2749–2753.

14. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, et al. (2006) Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of *Mycobacterium tuberculosis*. J Clin Microbiol 44:4498–4510.

## Author Contributions

Conceived and designed the experiments: AA WS NL. Performed the experiments: PB GD SA GM. Analyzed the data: AA WS PB NL. Contributed reagents/materials/analysis tools: VJ RC. Wrote the paper: AA WS NL.

15. Homolka S, Post E, Oberhauser B, George AG, Westman L, et al. (2008) High genetic diversity among *Mycobacterium tuberculosis* complex strains from Sierra Leone. BMC Microbiol 8:103.

16. Noeske J, Voelz N, Fon E, Abena Foe JL (2012) Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. BMC Res Notes 5:160.

17. Ramaswamy S, Musser JM (1998) Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: update. Tuber Lung Dis 79:3–29.

18. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, et al. (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of *Mycobacterium tuberculosis*. Antimicrob Agents Chemother 55:2032–2041.

19. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, et al. (2009) *Mycobacterium tuberculosis* strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 47:3501–3506.

20. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, et al. (2012) A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. J Antimicrob Chemother 67:819–831.

21. Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, et al. (2011) DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to *gyrB* mutations in *Mycobacterium tuberculosis*. Antimicrob Agents Chemother 55:4524–4529.

22. Umubeyci AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, et al. (2007) Limited fluoroquinolone resistance among *Mycobacterium tuberculosis* isolates from Rwanda: results of a national survey. J Antimicrob Chemother 59:1031–1033.

23. Mitarai S, Kafwafbulula M, Terunua H, Lubasi D, Kasolo FC, et al. (2005) *Mycobacterium tuberculosis* and *gyrA* variation in Zambia. Trop Med and Health 33:91–94.

24. Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, et al. (2013) Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis 13:432.

25. Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, et al (2014) Sensititre MYCOTB MIC plate for testing *Mycobacterium tuberculosis* susceptibility to first- and second-line drugs. Antimicrob Agents Chemother 58:11–8.

26. Hall L, Jude KP, Clark SL, Dionne K, Merson R, et al (2012) Evaluation of the Sensititre MycoTB plate for susceptibility testing of the *Mycobacterium tuberculosis* complex against first- and second-line agents. J Clin Microbiol 50: 3732–3734.

27. Godreuil S, Torrea G., Terru D, Chevenet F, Diagbouga S, et al. (2007) First molecular epidemiology study of *Mycobacterium tuberculosis* in Burkina Faso. J Clin Microbiol 45:921–927.

28. Groenheit R, Ghebremichael S, Svensson J, Rabna P, Colombatti R, et al. (2011) The Guinea-Bissau family of *Mycobacterium tuberculosis* complex revisited. PLoS One 6:e18601.

29. Agerton TB, Valway SE, Blinkhorn RJ, Shilkret KL, Reves R, et al. (1999) Spread of strain W, a highly drug-resistant strain of *Mycobacterium tuberculosis*, across the United States. Clin Infect Dis 29:85–92.

30. Dong H, Liu Z, Ly B, Zhang Y, Liu J, et al. (2010) Spoligotypes of *Mycobacterium tuberculosis* from different Provinces of China. J Clin Microbiol 48:4102–4106.
31. Drobniewski F, Balabanova Y, Nikolayevsky V, Ruddy M, Kuznetzov S, et al. (2005) Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 293:2726-2731.

32. Van Soolingen D, Qian L, de Haas PE, Douglas JT, Traore H, et al. (1995) Predominance of a single genotype of *Mycobacterium tuberculosis* in countries of East Asia. J Clin Microbiol 33:3234-3238.